Advertisement

Topics

FDA Approves Adjuvant Pembrolizumab in Stage III Melanoma

08:56 EST 19 Feb 2019 | OncLive

The FDA has approved the PD-1 inhibitor pembrolizumab for the adjuvant treatment of patients with high-risk stage III melanoma with lymph node involvement following complete resection. 

Original Article: FDA Approves Adjuvant Pembrolizumab in Stage III Melanoma

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Adjuvant Pembrolizumab in Stage III Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...